22nd October 2009
REGEN THERAPEUTICS PLC
("ReGen" or the "Company"; Ticker: (RGT))
TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES
1. Identity of the issuer or the underlying ReGen Therapeutics Plc
issuer of existing shares to which voting
rights are attached (ii):
2. Reason for the notification: An acquisition or
disposal of voting
rights
3. Full name of person(s) subject to the Barclays PLC
notification obligation (iii):
4. Full name of shareholder(s) (if difference Barclays Stockbrokers
from 3): Ltd
5. Date of the transaction and date on which 21st October 2009
the threshold is crossed or reached (v):
6. Date on which issuer notified: 22nd October 2009
7. Threshold(s) that is/are crossed or 13% to 12%
reached:
8. Notified details
A: Voting rights attached to shares
Class/type of share if possible using the ISIN GB00B28XMY25
Code
Situation Previous to the triggering
transaction (vi) -
Number of Shares 4,464,897
Number of Voting Rights (viii) 4,464,897
Resulting situation after the triggering
transaction (viii) -
Number of Shares 4,399,902
Number of Voting Rights - Direct (x) N/A
Number of Voting Rights - Indirect (xi) 4,399,902
% of voting rights - Direct N/A
% of voting rights - Indirect 12.85
B: Financial Instruments
Resulting situation after the triggering
transaction (xii)
Type of financial instrument N/A
Expiration date (xiii) N/A
Exercise/Conversion Period/Date (xiv) N/A
Number of voting rights that may be acquired N/A
if the instrument is exercised/converted
% of voting rights N/A
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments
Resulting situation after the triggering
transaction
Type of financial instrument N/A
Exercise Price N/A
Experation Date N/A
Number of voting rights N/A
Instrument refers to
% of voting rights N/A
Total (A+B+C)
Number of voting rights 4,399,902
% of voting rights 12.85
9. Chain of controlled undertakings through Barclays Stockbrokers
which the voting rights and/or the financial Ltd
instruments are effectively held, if
applicable (xv):
Proxy Voting:
10. Name of the proxy holder: N/A
11. Number of voting rights proxy holder will N/A
cease to hold:
12. Date on which proxy holder will cease to N/A
hold voting rights:
13. Additional information: N/A
14. Contact name: Geoff Smith
15. Contact telephone number: 0207 116 2913
For further information:
For further information, please contact:
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396
---END OF MESSAGE---
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.